Cargando…

Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy

Pulmonary embolism (PE) is associated with serious morbidity and mortality. In this case report, we describe a hemodynamically stable patient with submassive PE and a large thrombus in the inferior vena cava (IVC) protruding into the right atrium (RA), complicated by severe respiratory failure, elev...

Descripción completa

Detalles Bibliográficos
Autores principales: Vo, Anh Khoi, Reikvam, Håkon, Midtbø, Helga, Wirsching, Jan Ludvig, Bruserud, Øyvind, Wendelbo, Øystein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603563/
https://www.ncbi.nlm.nih.gov/pubmed/33149952
http://dx.doi.org/10.1155/2020/4219616
_version_ 1783603950622081024
author Vo, Anh Khoi
Reikvam, Håkon
Midtbø, Helga
Wirsching, Jan Ludvig
Bruserud, Øyvind
Wendelbo, Øystein
author_facet Vo, Anh Khoi
Reikvam, Håkon
Midtbø, Helga
Wirsching, Jan Ludvig
Bruserud, Øyvind
Wendelbo, Øystein
author_sort Vo, Anh Khoi
collection PubMed
description Pulmonary embolism (PE) is associated with serious morbidity and mortality. In this case report, we describe a hemodynamically stable patient with submassive PE and a large thrombus in the inferior vena cava (IVC) protruding into the right atrium (RA), complicated by severe respiratory failure, elevated troponin T (TnT), and right ventricular (RV) dysfunction. The patient was stratified as intermediate-high risk of early death. Important issues regarding the initial choice of anticoagulation, rescue thrombolytic therapy, and benefits of adding riociguat to stimulate the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway to improve the RV function are discussed. Finally, we address appropriate timing and the use of IVC filter in a situation of recurrent PE following anticoagulation and fibrinolytic therapy.
format Online
Article
Text
id pubmed-7603563
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-76035632020-11-03 Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy Vo, Anh Khoi Reikvam, Håkon Midtbø, Helga Wirsching, Jan Ludvig Bruserud, Øyvind Wendelbo, Øystein Case Rep Anesthesiol Case Report Pulmonary embolism (PE) is associated with serious morbidity and mortality. In this case report, we describe a hemodynamically stable patient with submassive PE and a large thrombus in the inferior vena cava (IVC) protruding into the right atrium (RA), complicated by severe respiratory failure, elevated troponin T (TnT), and right ventricular (RV) dysfunction. The patient was stratified as intermediate-high risk of early death. Important issues regarding the initial choice of anticoagulation, rescue thrombolytic therapy, and benefits of adding riociguat to stimulate the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway to improve the RV function are discussed. Finally, we address appropriate timing and the use of IVC filter in a situation of recurrent PE following anticoagulation and fibrinolytic therapy. Hindawi 2020-10-15 /pmc/articles/PMC7603563/ /pubmed/33149952 http://dx.doi.org/10.1155/2020/4219616 Text en Copyright © 2020 Anh Khoi Vo et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Vo, Anh Khoi
Reikvam, Håkon
Midtbø, Helga
Wirsching, Jan Ludvig
Bruserud, Øyvind
Wendelbo, Øystein
Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy
title Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy
title_full Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy
title_fullStr Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy
title_full_unstemmed Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy
title_short Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy
title_sort intermediate-high risk pulmonary embolism: the use of riociguat and inferior vena cava filter in a situation of recurrent embolism following insufficient anticoagulation and fibrinolytic therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603563/
https://www.ncbi.nlm.nih.gov/pubmed/33149952
http://dx.doi.org/10.1155/2020/4219616
work_keys_str_mv AT voanhkhoi intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy
AT reikvamhakon intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy
AT midtbøhelga intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy
AT wirschingjanludvig intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy
AT bruserudøyvind intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy
AT wendelboøystein intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy